179 related articles for article (PubMed ID: 15194166)
1. Rituximab in autoimmune diseases.
Virgolini L; Marzocchi V
Biomed Pharmacother; 2004 Jun; 58(5):299-309. PubMed ID: 15194166
[TBL] [Abstract][Full Text] [Related]
2. Rituximab in the treatment of autoimmune haematological disorders.
Garvey B
Br J Haematol; 2008 Apr; 141(2):149-69. PubMed ID: 18318765
[TBL] [Abstract][Full Text] [Related]
3. B cell-targeted therapy in diseases other than rheumatoid arthritis.
Looney RJ
J Rheumatol Suppl; 2005 Feb; 73():25-8; discussion 29-30. PubMed ID: 15693113
[TBL] [Abstract][Full Text] [Related]
4. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura.
Zhou Z; Yang R
Crit Rev Oncol Hematol; 2008 Jan; 65(1):21-31. PubMed ID: 17681784
[TBL] [Abstract][Full Text] [Related]
5. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells.
Liossis SN; Sfikakis PP
Clin Immunol; 2008 Jun; 127(3):280-5. PubMed ID: 18337174
[TBL] [Abstract][Full Text] [Related]
6. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse.
Levesque MC; St Clair EW
J Allergy Clin Immunol; 2008 Jan; 121(1):13-21; quiz 22-3. PubMed ID: 18206502
[TBL] [Abstract][Full Text] [Related]
7. B cell targeted therapies in autoimmune diseases.
Isenberg DA
J Rheumatol Suppl; 2006 May; 77():24-8. PubMed ID: 16652442
[TBL] [Abstract][Full Text] [Related]
8. A review of the current use of rituximab in autoimmune diseases.
Gürcan HM; Keskin DB; Stern JN; Nitzberg MA; Shekhani H; Ahmed AR
Int Immunopharmacol; 2009 Jan; 9(1):10-25. PubMed ID: 19000786
[TBL] [Abstract][Full Text] [Related]
9. Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome.
Pranzatelli MR; Tate ED; Travelstead AL; Longee D
Pediatrics; 2005 Jan; 115(1):e115-9. PubMed ID: 15601813
[TBL] [Abstract][Full Text] [Related]
10. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases.
El-Hallak M; Binstadt BA; Leichtner AM; Bennett CM; Neufeld EJ; Fuhlbrigge RC; Zurakowski D; Sundel RP
J Pediatr; 2007 Apr; 150(4):376-82. PubMed ID: 17382113
[TBL] [Abstract][Full Text] [Related]
11. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus.
Kumar S; Benseler SM; Kirby-Allen M; Silverman ED
Pediatrics; 2009 Jan; 123(1):e159-63. PubMed ID: 19074962
[TBL] [Abstract][Full Text] [Related]
12. B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis.
Looney RJ
Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii13-ii17. PubMed ID: 15851522
[TBL] [Abstract][Full Text] [Related]
13. [B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases].
Kondo S; Akashi T; Katsuta H; Iwakiri R; Anzai K; Nagafuchi S; Niho Y; Harada M
Fukuoka Igaku Zasshi; 2005 Apr; 96(4):86-92. PubMed ID: 15991605
[TBL] [Abstract][Full Text] [Related]
14. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders.
Stübgen JP
J Neuroimmunol; 2008 Nov; 204(1-2):1-12. PubMed ID: 18783837
[TBL] [Abstract][Full Text] [Related]
15. Rituximab: a B-cell depletion therapy for dermatologic disease.
Prajapati V; Mydlarski PR
Skin Therapy Lett; 2007; 12(6):6-9. PubMed ID: 17762903
[TBL] [Abstract][Full Text] [Related]
16. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.
Sfikakis PP; Boletis JN; Lionaki S; Vigklis V; Fragiadaki KG; Iniotaki A; Moutsopoulos HM
Arthritis Rheum; 2005 Feb; 52(2):501-13. PubMed ID: 15693003
[TBL] [Abstract][Full Text] [Related]
17. B-cell targeting in rheumatoid arthritis and other autoimmune diseases.
Edwards JC; Cambridge G
Nat Rev Immunol; 2006 May; 6(5):394-403. PubMed ID: 16622478
[TBL] [Abstract][Full Text] [Related]
18. B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders.
Edwards JC; Leandro MJ; Cambridge G
Biochem Soc Trans; 2002 Aug; 30(4):824-8. PubMed ID: 12196207
[TBL] [Abstract][Full Text] [Related]
19. Anti-B- cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus--an update.
Arin MJ; Hunzelmann N
Eur J Dermatol; 2005; 15(4):224-30. PubMed ID: 16048747
[TBL] [Abstract][Full Text] [Related]
20. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
